Having shown that PIK-75, a potent inhibitor of p110α, is a very effective TRAIL sensitizer, we next investigated whether specific inhibition of the p110α isoform of PI3K was capable of breaking TRAIL resistance in cancer cells and, hence, responsible for the PIK-75-mediated effect. Here, PIK3CD is linked to cancer.